1	
2	
3	Large-scale seroepidemiology uncovers nephrological pathologies
4	in people with tau autoimmunity
5	
6	
7	
8	Authors:
9	Andreia D. Magalhães ^{1†} , Marc Emmenegger ^{1&} , Elena De Cecco ¹ , Manfredi Carta ^{1‡} , Karl
10	Frontzek ^{1§} , Andra Chincisan ¹ , Jingjing Guo ¹ , Simone Hornemann ^{1*} , Adriano Aguzzi ^{1*}
11	
12	
13	
14	Affiliations:
15	¹ Institute of Neuropathology, University of Zurich; CH-8091 Zurich, Switzerland
16	* Correspondence: <u>simone.hornemann@usz.ch</u> and <u>adriano.aguzzi@usz.ch</u>
17	[†] Present address: Department of Neurology, Inselspital, Bern University Hospital; CH-3010
18	Bern, Switzerland
19	^{&} Present address: Division of Medical Immunology, Department of Laboratory Medicine, Uni-
20	versity Hospital Basel; CH-4031 Basel, Switzerland
21	[‡] Present address: Institute of Neurology, University of Zurich; CH-8091 Zurich, Switzerland
22	[§] Present address: University College London, Institute of Neurology, Queen Square Brain Bank;
23	WC1N 1PJ London, United Kingdom
24	^{II} Present address: Credit Suisse; CH-8001 Zurich, Switzerland
25	
26	
27	One Sentence Summary:
28	Anti-tau autoantibodies are prevalent, increase with age, and are associated with kidney and uri-
29	nary disorders.

30 Abstract:

31 Intraneuronal aggregates of the microtubule-associated protein tau play a pivotal role in Alz-32 heimer's disease and several other neurodegenerative syndromes. Anti-tau antibodies can reduce pathology in mouse models of neurodegeneration and are currently being tested in humans. Here, 33 34 we performed a large-scale seroepidemiological search for anti-tau IgG autoantibodies $(\alpha \tau)$ on 40,497 human plasma samples. High-titer $\alpha \tau^+$ individuals were surprisingly prevalent, with hospi-35 tal patients being three times more likely to be $\alpha \tau^+$ (EC₅₀ $\geq 2^6$) than healthy blood donors (4.8% vs 36 1.6%). Their autoantibodies bound selectively to tau, inhibited tau aggregation in vitro, and inter-37 fered with tau detection in plasma samples. No association was found between $\alpha \tau$ autoantibodies 38 and neurological disorders. Instead, tau autoreactivity showed a significant association with kidney 39 40 and urinary disorders (adjusted RR 1.27, 95% CI 1.10-1.45, P=0.001 and 1.40, 95% CI 1.20-1.63, P<0.001 respectively). These results identify a previously unrecognized association between $\alpha \tau$ 41 autoimmunity and extraneural diseases, inform clinical trials of anti-tau immunotherapies about 42 potential untoward effects, and uncover a prevalent confounder of immunoassay tau measurements 43 in plasma. 44

45 Main Text:

46 **INTRODUCTION**

47 Tau is a microtubule binding protein expressed in neurons and involved in cytoskeletal dynamics (1, 2). It plays a pivotal role in a variety of neurodegenerative diseases, including Alzheimer's 48 disease (AD) (3), progressive supranuclear palsy, and various syndromes collectively referred to 49 as tauopathies (4). The presence of brain neurofibrillary tau tangles correlates with cognitive de-50 51 cline (5), and plasma measurements of total and phosphorylated tau have emerged as promising biomarkers for the detection and monitoring of AD progression (6-9). Moreover, active and pas-52 sive immunization with antibodies against a wide range of tau epitopes can reduce pathology and 53 functional decline in animal models of tauopathies (10, 11) and are being tested in clinical trials 54 of neurodegenerative diseases (12). 55 Natural autoantibodies are immunoglobulins generated against self-antigens in the absence of ex-56 ternal antigen stimulation (13). They are a normal part of the immunoglobulin repertoire and have 57

58 physiological roles in homeostasis and surveillance, including the clearance of cellular debris, anti-

inflammatory activity, and first-line defense against pathogens (14). However, in certain situations,

60 natural autoantibodies can also cause pathological autoimmunity. The study of natural autoanti-

bodies can therefore inform about properties of their targets, e.g. unrecognized protective or con-

tributing roles in disease (15). Some natural autoantibodies can cause neurological disorders, such

63 as antibodies targeting the N-methyl-D-aspartate receptor (NMDAR) in encephalitis (16) or anti-

64 bodies targeting aquaporin-4 (AQP4) in neuromyelitis optica (17). Conversely, natural antibodies

against amyloid- β have been suggested to protect and slow the progression of AD; aducanumab,

a monoclonal antibody developed from B-cells of cognitively normal older age individuals, has
been studied as a treatment for AD (*18*).

Anti-tau autoantibodies have been detected in plasma of patients with AD (*19*) and Parkinson's disease (*20*), but also in non-neurodegeneration controls. The effects, if any, of natural anti-tau autoantibodies in modulating the risk of developing neurodegenerative diseases are unknown. The study of individuals with anti-tau autoantibodies could clarify their potential as modifiers or biomarkers of disease. Here, we tested 40,497 plasma samples from healthy blood donors and from patients admitted to a university hospital in the frame of a two-sites cross-sectional study. We found that anti-tau autoimmunity is highly specific and surprisingly frequent, with its prevalence

- 75 increasing with age. Unexpectedly, natural anti-tau autoantibodies were associated with a previ-
- 76 ously unrecognized syndrome comprising kidney and urinary disorders.

77 **RESULTS**

78 Prevalence of naturally occurring plasma anti-tau autoantibodies

We used a cross-sectional study design to assess naturally occurring IgG autoantibodies against 79 the microtubule-binding domain of the tau protein (MTBD-tau). Plasma samples from 32,291 pa-80 81 tients (age \geq 18 years) from an unselected university hospital cohort and from 8.206 healthy blood donors were screened for anti-MTBD-tau plasma IgG autoantibodies with a miniaturized ELISA 82 83 (Enzyme-Linked Immunosorbent Assay) in 1,536-well microplates using acoustic dispensing (21-84 23). Each plasma sample was tested at eight serial two-fold dilutions (1:50 to 1:6,000). Opticaldensity readings were fitted by logistic regression from which the inflexion points were derived. 85 Antibody titers were defined as " $-\log_{10}(EC_{50})$ ", i.e. the negative decadic logarithm of the plasma 86

87 dilution factor corresponding to the inflexion point of the respective regression curve.

88 After exclusion of non-informative samples (fitting error >20% -log₁₀(EC₅₀) or high background),

89 we included 24,339 patients' samples and 6,590 healthy blood donors' samples in the analysis

90 (Fig. 1A). A titer of $-\log_{10}(EC_{50}) \ge 1.8$, approximately corresponding to a nominal dilution of >

91 1/64, was selected as a cutoff to call tau-autoreactive samples (henceforth named $\alpha \tau^+$). Using these

parameters, 4.80% (n=1,169) of 24,339 patients' samples, but only 1.58% (n=104) of 6,590 healthy donors were $\alpha \tau^+$ (Fig. 1A-C). These data are indicative of a much higher prevalence of

94 anti-tau immunoreactivity in unselected hospital patients than in healthy individuals (P<0.001).

95 Demographic data was available for 4,157 of the 6,590 blood donors included in the study. Their

median age was 42 years (interquartile range [IQR] 29-54), whereas the median age of hospital

patients was 55 years (IQR: 40-69) (P<0.001). Of the healthy blood donors, 40.9% (n=1,698) were

98 women, whereas for the hospital group, 47.7% (n=11,609) of the patients were women (P<0.001).

99 Using a multivariate log-binomial regression model (24, 25) adjusted for age and sex, we found

100 that hospital patients had 2.3 times the risk of healthy donors to be $\alpha \tau^+$ (adjusted RR 2.30, 95%

101 confidence interval (CI) 1.83-2.92, P<0.001, Fig. 1D).

102 The replicability of the microELISA screen was evaluated by testing 308 randomly picked samples 103 in duplicate, and was found to be high (R^2 =0.84, P<0.001, Fig. 1E). To estimate any nonspecific 104 cross-reactivity, we determined the immunoreactivity to two other proteins implicated in neuro-105 degeneration, amyloid-ß pyroglutamate and the cellular prion protein (PrP^C) (22). Of 12,297 pa-106 tient samples, 604 samples were positive against MTBD-tau and 5 against amyloid-ß pyrogluta-107 mate but none was cross-reactive against both targets (P=1, χ^2 test) (Fig. 1F), Moreover, of 13,099

patient samples, 694 were reactive against MTBD-tau and 15 against PrP^{C} , but again none was cross-reactive against both targets (P=0.734, χ^2 test) (Fig. 1G)

110

111 Characterization of $\alpha \tau^+$ samples

112 Anti-tau autoantibodies were purified by MTBD-tau affinity chromatography from four individual $\alpha \tau^+$ patients (P1-P4) and from a pool of six $\alpha \tau^+$ samples for which larger sample volumes were 113 114 available. Their half-maximal effective concentration (EC₅₀) to MTBD-tau was determined by indirect ELISA and compared to the EC₅₀ of the well-characterized monoclonal anti-MTBD-tau an-115 tibody, RD4 (dissociation constant K_d =570 nM) (26). At equal concentrations, RD4 displayed 116 binding to MTBD-tau with EC₅₀=0.002 µg/ml Fig. 2A and no binding to MTBD-tau-free plates, 117 whereas the five purified autoantibody samples had EC_{50} values of 0.042-14.45 µg/ml (Fig. 2A). 118 As expected, no binding to MTBD-tau was observed for the unrelated antibody, Relatlimab (anti-119 LAG3) (27) (Fig. 2A). 120

To probe the binding specificity of the purified $\alpha \tau^+$ autoantibodies, we performed a soluble-com-121 petition immunoassay with MTBD-tau (Fig. 2B). This is a stringent assay which, when positive, 122 123 identifies high-affinity interactions. Purified autoantibodies from four $\alpha \tau^+$ patients and control were pre-incubated with either recombinant MTBD-tau, a pool of eight synthetic 25-meric pep-124 125 tides overlapping with each other by 10 residues and covering the MTBD-tau sequence, an unrelated synthetic 25-meric peptide derived from TREM2 (Triggering Receptor Expressed on Mye-126 127 loid Cells 2), or albumin. Each antigen was tested for its capability to impair the binding of purified $\alpha \tau^+$ autoantibodies to plate-bound MTBD-tau by ELISA. Pre-incubation with MTBD-tau and 128 129 pooled MTBD-tau peptides, but not with the TREM2 peptide or albumin, decreased the ELISA signal in a concentration-dependent manner (Fig. 2C). These results confirm the binding specific-130 131 ity of $\alpha \tau^+$ plasma for MTBD-tau.

132 Certain antibodies can display broad polyreactivity which may raise doubts about their specificity. 133 To probe for polyreactivity of purified $\alpha \tau^+$ autoantibodies, we performed indirect ELISA assays 134 against a variety of structurally different unrelated self-antigens and non-self-bacterial antigens, 135 including MTBD-tau, albumin, cardiolipin, DNA, insulin, and lipopolysaccharides (LPS) as well 136 as with uncoated plates. Purified anti-tau autoantibodies were reactive against MTBD-tau but not 137 against any of the tested antigens (Fig. 2D).

138 We then tested the purified $\alpha \tau^+$ autoantibodies by immunofluorescence staining and Western blot-139 ting. Purified anti-tau autoantibodies staining co-localized to cytoplasmic EGFP-0N4RTau in SH-140 SY5Y cells and showed similar specific binding to anti-tau mouse monoclonal antibody HT7, but not to non-transfected cells (Fig. 2E). Western blot analysis confirmed that purified $\alpha \tau^+$ autoanti-141 bodies detected tau-specific bands in cell lysates of SH-SY5Y cells overexpressing tau^{P301L/S320F}. 142 but not in wild-type (wt) SH-SY5Y cells (Fig. 2F and Fig. S1). These data provide substantial 143 144 evidence that the immunoreactivity observed in $\alpha \tau^+$ samples is indeed highly specific for tau. We further investigated the subclass composition of immunoglobulin heavy and light chains of 13 145 $\alpha \tau^+$ plasma samples. All four IgG subclasses were found, with IgG1 being detected in all 13 sam-146 ples, followed by IgG3 in 12 samples, IgG2 in 11 samples and IgG4 in 8 samples (Fig. 2G). κ light 147 chains were detected in 9 samples and λ light chains in 7 samples (Fig. 2H). Three samples were 148 polytypic for κ and λ (Fig. 2H). 149 We then profiled the epitopes recognized by the MTBD-tau autoantibodies in $\alpha \tau^+$ plasmas and of 150 MTBD-tau affinity chromatography purified autoantibodies from five $\alpha \tau^+$ samples (P2-P6) using 151 a library of 8 synthetic 25-meric peptides with 10 residues of overlap covering the sequence of 152 MTBD-tau. Most samples showed reactivity to peptides 3 (11 of 14) and 5 (10 of 14) which cor-153 respond to the repeat regions 2 and 3 of MTBD-tau (Figs 2I and S2). A polyclonal antibody re-154

156 (Fig. 2G-H). Taken together, these findings confirm the presence of naturally occurring antibodies 157 of different subclasses, light chains and against different epitopes of MTBD-tau in $\alpha \tau^+$ plasma

sponse was identified in at least 7 of 13 samples based on light-chain typing and epitope mapping

158 159 samples.

155

160 **Biological activity of** $\alpha \tau^+$ **autoantibodies**

Anti-tau antibodies can antagonize the aggregation of tau into pathogenic assemblies (28). To investigate whether plasma MTBD-tau autoantibodies interfere with the aggregation of MTBD-tau, MTBD-tau affinity purified autoantibodies from two further $\alpha \tau^+$ samples (P7 and P8) were subjected to an *in vitro* tau aggregation assay (28). MTBD-tau aggregation was induced by heparin and shaking and monitored using thioflavin T (ThT) (Fig. 3A). The presence of the anti-MTBDtau autoantibodies reduced the plateau of the ThT fluorescence signal in the kinetic trace by about half, whereas antibodies purified by protein G affinity chromatography from an $\alpha \tau^-$ patient had no

168 effect (Fig. 3A). These findings indicate that $\alpha \tau^+$ autoantibodies inhibit MTBD-tau aggregation *in* 169 *vitro*

170 Plasma tau is considered a possible biomarker for the progression of several neurological diseases (6-9, 29). To probe for an interference of $\alpha \tau^+$ autoantibodies in plasma tau immunoassays, we 171 added tau⁴⁴¹ to the plasma of healthy donors and examined the effect of $\alpha \tau^+$ autoantibodies onto 172 173 tau detection (Fig. 3B). Purified anti-MTBD-tau autoantibodies from 5 individual $\alpha \tau^+$ patients (P2-P6) were added to tau⁴⁴¹-spiked plasma. After incubation, the amount of free tau⁴⁴¹ was analyzed 174 by ELISA using the commercial anti-tau BT2 as a capture antibody (epitope on human tau⁴⁴¹: 175 residues 194-198) and ab64193 as a detection antibody (epitope on human tau⁴⁴¹ surrounding res-176 idue 262 (30)). We observed that purified anti-tau autoantibodies, P4-P6, induced a concentration-177 dependent impairment of detection of tau⁴⁴¹ (Fig. 3C-D) hampering the detection of plasma-spiked 178 tau⁴⁴¹ by up to approximately tenfold at higher anti-MTBD-tau autoantibodies concentrations (Fig. 179 180 3C-D). In contrast, P2-P3 did not show any significant impairment of the detection of plasmaspiked tau⁴⁴¹. This variability of interference is explained by the binding epitopes on tau⁴⁴¹. P4-P6 181 occupy tau residues 244 to 282 which include the epitope of the detection antibody ab64193, 182 whereas P2-P3 occupy residues 273 to 327 which are outside the binding epitope of ab64193 (Fig. 183 S2). We thus conclude that the presence of $\alpha \tau^+$ autoantibodies may interfere with the detection of 184 plasma tau in immunoassays depending on the combination of epitopes of the patient samples and 185 of the commercial antibodies used in the immunoassay. 186

187

188 **Demographic characteristics of tau-immunoreactive patients**

189 We performed univariate logistic regression analyses of basic demographic data available in the electronic health records for the 24,339 hospital patients. The age of $\alpha \tau^+$ patients (median: 58 years; 190 191 IQR: 43-71) was significantly higher than that of $\alpha \tau^{-}$ (median: 55; IQR: 40-68; P < 0.001, Fig. 4A). A more detailed breakdown of the date showed that the prevalence of $\alpha\tau$ immunoreactivity in-192 193 creased with age, from 3.9% in patients aged <29 years to 7.6% in patients older than 90 years 194 (P<0.001, Fig. 4B). A log-binomial regression model (24, 31) estimated that the risk ratio for the 195 presence of anti-MTBD-tau autoantibodies was highest for patients aged 70-99 years (RR 1.26, 95%CI 1.11-1.43, P<0.001, Fig. 4C) and for women (RR 1.20, 95%CI 1.07-1.39, P=0.002, Fig. 196 197 4C). Due to the association of anti-MTBD-tau autoantibodies with increased age and female sex,

all further risk ratios were calculated using a multivariate log-binomial regression model adjusted
for age and sex [age-and-sex adjusted risk ratio (aRR)].

Any possible correlations between $\alpha \tau^+$ and admission to specific clinical departments might inform on potential associations with specific diseases. The highest age-and-gender adjusted risk ratios for $\alpha \tau^+$ were found for the departments of angiology (RR 1.84, 95%CI 1.21-2.63, P=0.002) and nephrology (RR 1.50, 95%CI 1.16-1.89, P=0.001, Fig. 4D-E). Importantly, no significant difference was found between the percentage of $\alpha \tau^+$ and $\alpha \tau^-$ patients from the department of neurology

205 206 (Fig. 4D).

207 Neurological disorders and anti-tau autoimmunity

208 We next mined pseudonymized clinical data pertaining to the diagnoses of 23,375 patients as represented by ICD-10 codes (International Classification of Disease and Related Health Problems, 209 210 10th revision) (Fig. 5A). Given the involvement of tau in neurodegenerative diseases (3), we focused on evaluating the association between anti-MTBD-tau autoantibodies and neurological dis-211 212 ease, which we categorized in 23 main groups of disorders. No associations between $\alpha\tau$ + and neu-213 rological diseases were identified (Fig. 5A). To further validate this finding, we performed a tar-214 geted screen using plasma samples from 47 patients with AD and 68 similarly aged non-AD pa-215 tients selected from our plasma biobank (Table S1). Samples were tested for anti-MTBD-tau IgG autoantibodies, as in the primary screen, and additionally for anti-MTBD-tau IgA autoantibodies 216 and anti-full-length tau IgG and IgA autoantibodies. No significant difference in reactivity was 217 218 observed between the plasma samples from AD patients and non-AD controls (Fig. 5B), support-219 ing the hypothesis that the presence of autoantibodies targeting MTBD-tau is unrelated to AD or other neurological disorders. 220

221

222 Systemic disorders and anti-tau autoimmunity

We next assessed possible associations between tau autoimmunity and extraneural diseases, which
we binned into 27 main groups of disorders (Fig. 6A). After adjustment for multiple comparisons,
at immunoreactivity showed significant associations with vascular disorders (adjusted RR 1.51,
95%CI 1.28-1.77, P<0.001), nutritional disorders (adjusted RR 1.31, 95%CI 1.14-1.50, P<0.001),
anemia (adjusted RR 1.49, 95%CI 1.21-1.82, P<0.001), kidney disorders (adjusted RR 1.27,
95%CI 1.10-1.45, P=0.001) and urinary disorders (adjusted RR 1.40, 95%CI 1.20-1.63, P<0.001)

(Fig. 6B), whereas no association was observed among patients with autoimmune disorders (Fig.

S3). There was no difference in the coincidence of all comorbidities between the $\alpha \tau^+$ samples (5,

231 0.46%) and the $\alpha \tau$ samples (69, 0.33%) (P=0.633).

To address potential biases arising from grouping and selecting major categories, we further ex-232 233 plored the association between $\alpha \tau^+$ and individual ICD-10 codes. Across 276 individual ICD-10 codes and after correction for multiple comparisons, eight exhibited significant associations with 234 235 $\alpha \tau^+$ (Fig. 6B-C). These included "E61 – deficiency of other nutrient elements" (adjusted RR 2.22, 95%CI 1.54-3.06, P<0.001), "I74 - arterial embolism and thrombosis" (adjusted RR 2.09, 95%CI 236 1.40-2.94, P<0.001), "N30 - cystitis" (adjusted RR 1.84, 95% CI 1.32-2.47, P<0.001), "I70 - ath-237 erosclerosis" (adjusted RR 1.57, 95%CI 1.29-1.89, P<0.001), "D50 - iron deficiency anemia" 238 239 (adjusted RR 1.50, 95%CI 1.21-1.82, P<0.001), "N39 – other urinary disorders" (adjusted RR 1.40, 95% CI 1.19-1.64, P<0.001), "B96 - other bacterial agents as the cause of diseases" (adjusted 240 RR 1.40, 95% CI 1.17-1.66, P<0.001) and "N18 – chronic kidney disease" (adjusted RR 1.38, 241 95%CI 1.18-1.60, P<0.001) (Fig. 6C). Again, it is well-known that many of these diseases are 242 often co-incident in clinical practice. Conversely, we found no significant negative association 243 244 between tau autoreactivity and any ICD-10 codes that could suggest a decreased risk for a specific disease in $\alpha \tau^+$ patients (Fig. 6B). 245

To further verify the association between $\alpha \tau^+$ and individual ICD-10 codes, we used a different statistical approach. Instead of using a titer of $-\log_{10}(EC_{50}) \ge 1.8$ to dichotomize samples as positives and negatives, we performed a Bayesian logistic regression using logit-transformed EC₅₀ values (-logit[EC₅₀]) as a continuous outcome. We could verify that all the previously referred eight ICD-10 codes showed positive associations with -logit[EC₅₀] (Fig. 6D).

With the aim of further validating these conditions as clinically significant associations with 251 252 plasma MTBD-tau IgG autoantibodies, we examined the association between $\alpha \tau^+$ and 106 commonly requested laboratory parameters using data available for 24,177 patients. This analysis was 253 254 independent of any ICD-10 classifiers. After correction for multiple comparisons, the laboratory markers "Leukocytes, urine", "Potassium" and "Urea" were positively associated with tau auto-255 256 immunity (Fig. 6E). The association with increasing levels of urea and potassium suggest a link to 257 kidney failure, whereas leukocytes in urine are a feature of urinary tract infections. These findings 258 are therefore in good agreement and provide a strong independent line of evidence for the hypoth-259 esis that anti-tau autoimmunity correlates with such disorders.

Comparing the prevalence of kidney and urinary disorders in $\alpha \tau^-$ and $\alpha \tau^+$ patients, we identified an excess prevalence of chronic kidney disease of 5.3% in $\alpha \tau^+$ patients (12.4% in $\alpha \tau^-$ and 17.7% in $\alpha \tau^+$), an excess prevalence of cystitis of 1.7% in $\alpha \tau^+$ patients (1.6% in $\alpha \tau^-$ and 3.3% in $\alpha \tau^+$), and an excess prevalence of other urinary disorders of 4.8% (10.3% in $\alpha \tau^-$ and 15.1% in $\alpha \tau^+$) (Fig. 6F). These data further support the hyperprevalence of tau autoimmunity in patients with these diseases.

266 **DISCUSSION**

267 Due to their hypothesis-free character and their independence from priors, large-scale seroepide-268 miological screens have the potential to uncover disease correlations and new biological effects of its targets that may not be discoverable in any other way. Such screens are suited to identifying 269 270 pathologies correlating with any immunoreactivity, but require economical, massively parallel assays. Using acoustic dispensing and extensive customized automation, we miniaturized antibody 271 272 detection to a volume of 3 µl/sample and to 1,536-well microplates. This allowed us to run 40,000 273 assays/24 hrs using a robotic platform. In total, we performed >300,000 immunoassays on >40,000plasma samples obtained from university hospital patients and healthy blood donors for at auto-274 reactivity (21-23). ELISA miniaturization lowered the cost of individual assays, allowing us to 275 measure eight data points across a dilution range of 1:50 to 1:6,000 for each sample. Consequently, 276 this method enables us to determine autoantibody titers more stringently and unambiguously (21-277 23). 278

Even after adjustments for age and sex, the $\alpha \tau^+$ rate in hospital patients was three-fold higher than 279 in healthy blood donors and was 2.4 times higher than that of autoantibodies targeting other intra-280 281 cellular neuronal targets reported by others (32). Plasma $\alpha\tau$ IgG correlated with female sex and increased with age. The specificity of $\alpha \tau^+$ plasma to MTBD-tau was high and was confirmed by 282 multiple orthogonal assays including epitope mapping. Most $\alpha \tau^+$ samples were polyclonal, and all 283 IgG subclasses were represented. Purified $\alpha\tau$ autoantibodies exhibited the capability to inhibit 284 285 MTBD-tau aggregation *in vitro*. Finally, it was possible to compete them by MTBD-tau and a pool of synthetic MTBD-tau peptides, but not by other antigens. 286

287 The much higher prevalence of $\alpha\tau$ positivity in hospital patients than in healthy blood donors suggests that tau autoreactivity is low in healthy populations and that $\alpha \tau$ autoantibodies are associated 288 289 with disease. However, we did not find any association between $\alpha \tau^+$ and any neurological conditions including neurodegenerative diseases. This observation is compatible with reports of similar 290 291 levels of plasma tau autoantibodies in Alzheimer's disease patients and non-demented controls (33). Instead, we uncovered a robust and specific association between plasma anti-MTBD-tau IgG 292 293 autoantibodies and the diagnosis of kidney and urinary disorders, which was validated by the in-294 dependent finding of association between $\alpha \tau$ immunoreactivity and higher prevalence of positive

samples from the department of Nephrology, grouped kidney and urinary diseases, individual kidney and urinary diagnosis codes as well as high serum urea and potassium and high urine leukocytes, which are clinical laboratory biomarkers of kidney and urinary disorders.

This seroepidemiological studies cannot establish causality: hence $\alpha \tau$ seropositivity could be a 298 299 cause or a consequence of the clinical syndromes associated with it. Indeed, some patients with frontotemporal dementia and Parkinsonism caused by mutant tau experience urinary incontinence 300 301 (34) which may plausibly result from neuronal pathologies. However, tau is expressed in extraneu-302 ral tissues, including kidney podocytes and urinary bladder (2, 35-37), and its ablation causes glomerular pathologies (38). Besides raising the possibility that plasma $\alpha \tau$ autoantibodies might drive 303 kidney pathologies, these findings suggest that such autoantibodies represent useful biomarkers of 304 305 these diseases. Finally, these findings suggest that it will be important to monitor renal and urinary function in the current clinical trials of tau immunotherapy (39-41). 306

307 Recent studies have explored the use of total and phosphorylated tau measurements in plasma as biomarkers for AD diagnosis and for monitoring its progression (6-9, 29, 42-46). Measurement of 308 plasma tau levels may enter regular clinical use as an easily accessible biomarker of AD. However, 309 310 we found that anti-MTBD-tau autoantibodies could hinder tau detection in plasma by binding to 311 epitopes recognized by commercial biomarker immunoassays. This aligns with prior research in-312 dicating that both plasma anti-tau autoantibodies and administered anti-tau antibodies can influ-313 ence the dynamics of tau levels in plasma (47). Additionally, a recent community cohort study 314 using an immunoassay for AD screening revealed associations between plasma tau levels and nu-315 merous comorbidities, with chronic kidney disease showing one of the strongest associations (48). 316 These results imply that the presence of anti-tau autoantibodies in plasma might impact the effectiveness of plasma tau as an AD biomarker, particularly for patients with kidney or urinary dis-317 318 eases. This consideration may become crucial as plasma tau levels move toward routine clinical 319 use in AD diagnosis.

Our large-scale assessment of plasma tau autoimmunity has certain limitations. Firstly, most samples analyzed in our study came from a university hospital cohort, implying a bias towards complex pathologies and polymorbidities. To account for this, we included a vast collection of samples from healthy blood donors. Secondly, our study is confined to two sites within a single region with approximately 1,500,000 inhabitants whose ethnic composition was not thoroughly examined. Additionally, a direct comparison of the prevalence of plasma anti-tau antibodies in these two cohorts

326 may potentially suffer from variations in materials, collection methods, and handling processes at

- 327 the two different sites. Thirdly, our study is restricted to the analysis of specific disease groups and
- 328 the absence of a longitudinal disease cohort that would allow for examining a time course, origin,
- 329 and causal role of these autoantibodies. Finally, we used bacterially expressed MTBD-tau as target,
- thereby excluding full-length or post-translationally modified tau epitopes. As a result, plasma
- anti-tau autoantibodies associated with AD pathology might be missed, and our methodology may
- 332 underestimate the prevalence of total anti-tau autoantibodies.
- 333 In conclusion, our study found a high seroprevalence of anti-MTBD-tau IgG autoantibodies in
- both plasma samples from university hospital patients and healthy blood donors. Tau autoimmun-
- ity is associated with female sex, older age and previously unrecognized extraneural diseases.
- 336 These findings point to unrecognized roles for tau and anti-tau autoantibodies in extraneural pa-
- thologies and call for attentive clinical monitoring of such diseases in clinical trials of tau-targeting
- therapies and in the use of plasma tau as a biomarker of disease.

339

340 MATERIALS AND METHODS

341 Study design

342 Collection of samples and clinical data were conducted according to study protocols approved by 343 the Cantonal Ethics Committee of the Canton of Zurich, Switzerland (KEK-ZH Nr. 2015-0561, 344 BASEC-Nr. 2018-01042, and BASEC-Nr. 2020-01731). From December 2017 until February 345 2020, residual heparin plasma samples were obtained from the Department of Clinical Chemistry, University Hospital of Zurich), Switzerland. Blood samples were collected during routine clinical 346 care from patients admitted either as inpatients or outpatients and were only included if basic de-347 mographic data was available, age was ≥ 18 years, and an informed consent for research had been 348 provided. From March until July 2020, EDTA plasma samples were obtained from the Blood Do-349 nation Center of Zurich, Switzerland from blood donors according to standard criteria of blood 350 donation. Exclusion criteria were as shown previously (21). Plasma samples were biobanked in 351 384-well plates at the Institute of Neuropathology, University of Zurich and tested on an automated 352 indirect microELISA high-throughput platform for natural IgG autoantibodies against the micro-353 354 tubule-binding-domain of tau (MTBD-tau, tauK18, for details see (21, 22) and below). 355 Demographic and clinical data for the hospital cohort was obtained from clinical electronic records

- of the University Hospital of Zurich with follow-up until December 2021, while detailed clinical
 data for the blood donor cohort were not available for this study.
- 358 For the AD targeted screen, the AD patients and non-neurodegeneration controls were selected
- 359 from the biobank of samples at the Institute of Neuropathology, USZ, using International Statis-
- 360 tical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes. AD
- 361 patients were defined using ICD-10 code F00 or G30 and non-neurodegeneration controls were
- defined by the lack of any Fxx or Gxx ICD-10 codes.

363 Automated microELISA screen

Plasma samples were tested for natural anti-MTBD-tau IgG autoantibodies in a microELISA screen (21-23). Briefly, high-binding 1,536-well plates (Perkin Elmer, SpectraPlate 1536 HB) were coated with 1 μ g/mL of in-house produced MTBD-tau (see protocol below) at 37 °C for 60 min. Plates were washed 3x with phosphate-buffered saline 0.1% Tween®20 (PBST) using a Biotek El406 washer-dispenser. Plates were blocked for 90 min with 5% milk (Migros) in PBST. Plasma was diluted 1:20 in 1% milk in PBST and dispensed into the MTBD-tau-coated plates using ultrasound dispensing with an ECHO 555 Liquid Handler (Labcyte/Beckman Coulter) and

in different volumes to a final volume of 3 µL/well and testing each sample at eight serial two-fold 371 372 dilutions (1:50 to 1:6,000). Human IgG-depleted serum (MyBioSource) was used as negative con-373 trol and anti-tau RD4 (4-repeat isoform) mouse monoclonal antibody (05-804 clone 1E1/A6 Merck Millipore) as a positive control. Samples were incubated for 120 min at room temperature (RT) 374 375 after which plates were washed 5x with PBST. Secondary antibody peroxidase AffiniPure® goat anti-mouse IgG H+L (115-035-003, Jackson ImmunoResearch) at 1:2,000 dilution in 1% milk 376 377 PBST for the RD4 positive control, and peroxidase AffiniPure® goat anti-human IgG Fcy-specific 378 (109-035-098, Jackson ImmunoResearch) 1:4,000 dilution in 1% milk PBST for the plasma samples and the IgG-depleted serum negative control were dispensed into the plates using a Biotek 379 MultifloFX dispenser. Secondary antibodies were incubated for 60 min at RT after which plates 380 381 were washed 3x with PBST. 3,3',5,5'-Tetramethylbenzidine (TMB) Chromogen Solution for ELISA (Invitrogen) was added to the plates as colorimetric horseradish peroxidase (HRP) sub-382 strate and incubated for 3 min at RT. Finally, 0.5 M H₂SO₄ was added to stop the reaction. Plates 383 were briefly centrifuged after each dispensing step except after dispensing of TMB. Plates were 384 read at Optical Density (OD) = 450 nm in a plate reader (Perkin Elmer, Envision). 385

For the replicability assessment, 308 samples were tested in duplicates using the same protocol as described before, and running the replicates on the same day but using different 1536-well assay (destination) plates, different plate coordinates for each replicate, and calculating the $-\log_{10}(EC_{50})$ of each replicate independently.

Non-specific cross-reactivity was assessed by testing plasma samples against against-MTBD-tau
 and amyloid-β pyroglutamate (13,099 hospital patients' plasma samples) and the cellular prion

392 protein (PrP^C) (12,297 hospital patients' samples) using a similar protocol as described above.

393 Production and purification of recombinant tau

The gene encoding the human truncated 4R-tau corresponding to the microtubule binding domain of tau protein (MTBD-tau) was cloned into a pRSET-A plasmid (Invitrogen). For protein expression the respective vector was transformed into *E.coli* BL21(DE3) cells. Bacterial cells were grown in Luria Broth (LB) medium (Invitrogen) at 37 °C until an OD₆₀₀ of 0.8 was reached and were then induced with isopropyl- β -D-thiogalactoside (IPTG) at a final concentration of 1 mM. After growing the cells for additional 6 h at 37 °C, cultures were harvested by centrifugation (6,000*g*, 10 min, 4 °C). Pellets were suspended in 20 mM piperazine-N,N-bis(2-ethanesulfonic) acid (PIPES), pH

402 sonicated for 30 min at 4 °C. NaCl to 500 mM final concentration was added, samples were boiled at 95 °C for 20 min and centrifuged (9,000g, 30min, 4 °C). Ammonium sulfate was slowly added 403 404 to a final concentration of 55% m/v and stirred for 1 h at room temperature (RT). Samples were centrifuged (15,000g, 10min, 4 °C), pellets were resuspended in 20 mM 4-(2-hydroxyethyl)piper-405 406 azine-1-ethanesulfonic acid (HEPES) (pH 7.0), 2 mM dithiothreitol (DTT), passed through a 0.45 µm Acrodisc® filter (Sigma) and loaded onto Sepharose SP Fast Flow resin (Cytiva). Tau was 407 408 eluted using a linear salt gradient from 0 to 1 M NaCl in 20 mM HEPES, pH 7.0, 2 mM DTT. 409 Fractions containing tau were concentrated using Amicon® Ultra-15 centrifugal filter unit (10kDa MWCO) (Merck) and dialyzed overnight at 4°C against phosphate-buffered saline (PBS) (pH 410 7.4) (Kantonsapotheke Zurich), 1mM DTT. Pooled samples were passed through a HiLoad 26/60 411 Superdex75 (GE Healthcare) column. Protein samples were analyzed by SDS-PAGE and samples 412 containing tau were concentrated using an Amicon® Ultra-15 centrifugal filter unit (10-kDa 413 MWCO). Samples were assessed by SDS-PAGE and electrospray ionization-mass spectrometry 414 (Functional Genomics Center Zurich, Switzerland). Pure MTBD-tau samples were stored until 415 further use at -80°C. The concentration of tau was determined using a bicinchoninic acid assay 416 417 (Pierce BCA Protein Assay Kit, Thermo Fisher).

For the purification of full-length tau, a similar protocol was used with the following changes. The
gene encoding the longest 4R isoform of human full-length tau protein, tau⁴⁴¹, (tau/pET29b,
Addgene #16316, gift from Peter Klein (49)) was cloned into a pRSET-A plasmid (Invitrogen).
For protein expression, E.*coli* BL21(DE3)pLysS cells were transformed with the pRSET-A plasmid encoding tau⁴⁴¹. Cells were grown in Overnight Express[™] Instant TB media (Novagen) for 6
h at 37 °C and then 12 h at 25 °C. Fractions containing full-length tau were concentrated using
Amicon® Ultra-15 centrifugal filter unit (30-kDa MWCO) (Merck).

425 **Purification of anti-tau autoantibodies from patient samples**

426 Heparin plasma (between 3 mL and 20 mL per hospital cohort patient) was diluted 1:3.3 in PBS,

427 and centrifuged (6,000 g, 10 min, 4 $^{\circ}$ C). The supernatant was loaded on a column containing 3 mL

428 of epoxy-MTBD-tau (prepared with a previous overnight incubation of MTBD-tau and epoxy resin

- 429 in a binding buffer of 0.1 M NaH₂PO₄–NaOH, 1 M NaCl, pH 9.2) by repetitive loading of the
- 430 plasma sample overnight at 4 °C. The column was washed with 50 mL of PBS, and MTBD-tau
- 431 autoantibodies were eluted four times with 5 mL 0.1 M glycine–HCl, pH 2.5, and immediately
- 432 neutralized to pH 7.0 with 1 M Tris-HCl. Fractions containing antibodies against MTBD-tau were

identified using an indirect colorimetric ELISA. Fractions containing the eluted antibodies were
stepwise concentrated using Amicon® Ultra-15, Ultra-4, and Ultra-0.5 mL centrifugal filter units

435 (50-kDa MWCO) to up to a volume of 1 mL.

436 **Competitive ELISAs**

437 For the competitive ELISAs of MTBD-tau autoantibodies, high-binding 384-well plates (Perkin Elmer, SpectraPlate 384 HB) were coated with 20 µL of 0.5 µg/mL of MTBD-tau at 4 °C over-438 439 night. Afterwards, plates were washed 3x with PBST with a Biotek El406 washer dispenser and blocked with 5% SureBlockTM (Lubio) in PBST for 120 min. Purified autoantibodies from hospital 440 cohort patients' plasma were diluted 1:50 in 1% SureBlock[™] (Lubio) in PBST (sample buffer). 441 Anti-tau RD4 mouse monoclonal antibody (05-804 clone 1E1/A6 Merck Millipore) was diluted to 442 443 a final concentration of 0.4 µg/mL. Bovine serum albumin (Thermo Scientific), in house purified recombinant MTBD-tau, a pool of eight synthetic peptides covering the sequence of MTBD-tau 444 with 25 amino acids length and 10 amino acids of overlap (Genscript) and an unrelated 25 amino 445 acid length synthetic TREM2 (Triggering receptor expressed on myeloid cells 2) peptide 446 (GenScript) were used as competing antigens. Antibody samples were incubated overnight at 4°C 447 448 with serial 2-fold dilutions of antigens solutions in sample buffer from 20,000 nM to 2.44 nM final 449 concentration. Antibody-antigen solutions were added to the plates and incubated for 45 min at 450 RT. Plates were washed 3x with PBST using a Biotek El406 washer dispenser and secondary antibodies were added as follows: peroxidase AffiniPure® goat anti-Human IgG (H+L) (109-035-451 452 088, Jackson ImmunoResearch) diluted 1:3,000 and peroxidase AffiniPure® goat anti-mouse IgG 453 H+L (115-035-003, Jackson ImmunoResearch) diluted 1:2,000. Secondary antibodies were incu-454 bated for 60 min at RT and then plates were washed plates 4x with PBST. TMB Chromogen Solution for ELISA (Invitrogen) was added to the plates and incubated for 7 min at RT. Finally, 0.5 455 456 M H₂SO₄ was added. Plates were briefly centrifuged after each dispensing step except after dispensing colorimetric substrate. Plates were read at OD = 450 nm in a plate reader (SpectraMax® 457 458 Paradigm[®], Molecular Devices).

For the competitive sandwich ELISAs for the detection of tau in plasma, a similar approach was applied with several changes. High-binding 384-well plates (Perkin Elmer, SpectraPlate 384 HB) were coated with $4 \mu g/mL$ BT2 tau monoclonal antibody (epitope on human tau, RSGYS, between residue 194 and 198) (#MN1010, Thermo Fisher) in PBS. Samples were diluted in sample buffer as follows: recombinant human tau⁴⁴¹ (rPeptide) was diluted to a final concentration of 0.015

464 ng/mL and incubated with purified anti-tau autoantibodies four-fold serially diluted (1:1.66 to 1:106.6) in 1:2 plasma for 120 min at 37°C with rotation at 500 rpm. Samples were transferred to 465 466 BT2 antibody-coated plates and incubated for 45 min at RT. Plates were then washed 4x with PBST and ab64193(epitope Ser262 on non-phosphorylated and phosphorylated of human tau) pol-467 yclonal IgG antibody (Abcam) at 0.125 µg/mL was incubated for 45 min at RT. Plates were 468 washed 4x with PBST and peroxidase AffiniPure® goat anti-Rabbit IgG (H+L) (111-035-045, 469 470 Jackson ImmunoResearch) diluted 1:2,000 was incubated 60min at RT. Plates were washed plates 4x with PBST, and 1-Step[™] Ultra TMB-ELISA solution (Thermo Fisher) was incubated for 7 min 471 at RT. After addition of 0.5 M H_2SO_4 , plates were read at OD = 450 nm in a plate reader (Perkin 472

474 Indirect ELISAs

Elmer, Envision).

473

To test for polyreactivity, purified anti-tau autoantibodies were tested by indirect ELISA against 475 476 several antigens (50, 51). High-binding 384-well plates (Perkin Elmer, SpectraPlate 384 HB) were coated with 1 µg/mL of in house purified MTBD-tau in PBS, 10 µg/mL of double stranded DNA 477 from calf-thymus (Sigma) in PBS, 10 µg/mL of lipopolysaccharides from E. coli O111:B4 (Sigma) 478 in PBS, 5 µg/mL of human recombinant insulin (Sigma) in PBS, 10 µg/mL of bovine serum albu-479 480 min (Thermo Fisher) in PBS, 2 µg/mL of cardiolipin solution from bovine heart (Sigma) in ethanol or left high-binding plates uncoated at 4 °C overnight. Plates were washed 3x with PBST using a 481 Biotek El406 washer dispenser and then blocked 5% SureBlock[™] (Lubio) in PBST for 120 min 482 483 at RT. The following samples serially diluted 1:1 in sample buffer were incubated for 120 min at RT: patient purified anti-tau autoantibodies were diluted 1:33, human IgG-depleted plasma (Bio-484 485 Source) was 1:50 diluted and used as a negative control, anti-DNP (Sigma) was diluted to a final concentration of 6 µg/mL and used as a positive control for cardiolipin, DNA and albumin coated 486 487 plates, anti-tau RD4 mouse monoclonal antibody (05-804 clone 1E1/A6 Merck Millipore) was diluted to a final concentration of 6 µg/mL and used as a positive control for MTBD-tau coated 488 489 plates, pooled plasma from 20 patients (Institute Clinical Chemistry (IKC), University Hospital 490 Zurich) was diluted 1:25 and used as a positive control for insulin, lipopolysaccharides and un-491 coated plates. Plates were then washed 4x with PBS-T using a Biotek El406 washer dispenser. Secondary antibodies were diluted and incubated for 60 min at RT as follows: peroxidase Affini-492 493 Pure® goat anti-human IgG (H+L) (109-035-088, Jackson ImmunoResearch) diluted 1:3,000 and added to purified MTBD-tau autoantibodies and IKC pool wells, peroxidase AffiniPure® goat 494

anti-mouse IgG H+L (115-035-003, Jackson ImmunoResearch) diluted 1:2,500 and added to anti-RD4 wells, and peroxidase AffiniPure® goat anti-rabbit IgG (H+L) (111-035-045, Jackson ImmunoResearch) diluted 1:4,000 and added to anti-DNP wells. Plates were washed plates 4x with PBST. TMB Chromogen solution for ELISA (Invitrogen) was incubated for 7 min at RT. Finally, 0.5 M H₂SO₄ was added. Plates were briefly centrifuged after each dispensing step except after dispensing colorimetric substrate. Plates were read at OD = 450nm in a plate reader (SpectraMax® Paradigm®, Molecular Devices).

502 For relative affinity measurements, we used a similar approach with the following modifications. An indirect ELISA in 384-well plates (Perkin Elmer, SpectraPlate 384 HB) with MTBD-tau as a 503 coating antigen, was used. The starting concentration of all antibodies, assayed in triplicates, was 504 505 10 μ g/mL. They were successively diluted 1:3 to reach a concentration of 2x10⁻⁶ μ g/mL. As reference antibody, we used purified RD4 kindly provided by Prof. Rohan de Silva (UCL Queen 506 507 Square Institute of Neurology, London, UK). As additional controls, we used anti-LAG3 (Lymphocyte Activation Gene 3) antibody Relatlimab (27), $\alpha\tau^{-}$ plasma sample and uncoated plates. The 508 respective EC₅₀ values were determined using logistic regression, as described below. 509

510 For IgG subclassing, the following secondary antibodies were used: rabbit anti-human IgG1 (SA5-

511 10202, Invitrogen), rabbit anti-human IgG2 (SA5-10203, Invitrogen), rabbit anti-human IgG3

512 (SA5-10204, Invitrogen) or rabbit anti-human IgG4 (SA5-10205, Invitrogen) diluted 1:1,500, pe-

513 roxidase AffiniPure® goat anti-rabbit IgG (H+L) antibody (111-035-045, Jackson Immu-

514 noResearch) diluted 1:2,500.

515 For immunoglobulin light chain typing, the following secondary antibodies were used: peroxidase 516 goat anti-human κ (22) 1:4,000 diluted, peroxidase goat anti-human λ (22) 1:4,000 diluted.

517 For epitope mapping, a similar approach was used: high-binding 384-well plates (Perkin Elmer,

518 SpectraPlate 384 HB) with 1 µg/mL of each individual MTBD-tau synthetic peptide (GenScript)

519 diluted in PBS at 4 °C overnight. 8 synthetic peptides spanning the sequence of MTBD-tau with

520 25 amino acids length and 10 amino acids of overlap were used. Plasma samples were diluted 1:50,

521 human IgG-depleted serum (MyBioSource) was 1:50 diluted and used as a negative control and

522 anti-tau RD4 mouse monoclonal antibody (05-804 clone 1E1/A6 Merck Millipore) was diluted to

523 a final concentration of 6 µg/mL and used as a positive control. The following secondary antibod-

524 ies diluted in sample buffer were used: peroxidase AffiniPure® goat anti-human IgG (H+L) (109-

- 525 035-088, Jackson ImmunoResearch) diluted 1:5,000 and peroxidase AffiniPure® goat anti-mouse
- 526 IgG H+L (115-035-003, Jackson ImmunoResearch) diluted 1:2,500 and added to anti-RD4 wells.

527 In vitro MTBD-tau aggregation assay

- 528 MTBD-tau *in vitro* aggregation experiments were performed as previously described (28). Briefly,
- 529 $7 \mu M$ of in house purified recombinant MTBD-tau, 3.5 μM of heparin (Santa Cruz Biotechnology)
- 530 and 10 μM of thioflavin T (ThT, Sigma) were diluted in PBS. The patient purified anti-tau auto-
- antibodies and controls (plasma sample reactive against the LAG3 and IgG-purified using Protein
- 532 G Sepharose (Cytiva)) were added at the indicated apparent stoichiometries in Fig. 3A and the
- mixtures with a total volume of $200 \,\mu$ l were added to black 96-well polystyrene microplates (Nunc,
- Prod. No. 265301). Measurements of ThT fluorescence (450/480 nm ex/em filters; bottom read
- mode) were performed at 37°C under continuous orbital shaking (425 cpm) every 15 min for 96 h
- 536 in a FLUOstar Omega microplate reader (BMG Labtech).

537 Western blotting

- SH-SY5Y wild-type cells (Sigma) and SH-SY5Y cells overexpressing double-mutant tau^{P301L/S320F}
 were lysed in 0.5% Triton[™] X-100 (Sigma Aldrich) in PBS, supplemented with cOmplete[™] Mini
- EDTA-free Protease Inhibitor Cocktail (Roche) on ice and supernatant was recovered after centrifugation (14,000g, 20min, 4°C). Protein concentration was estimated using a bicinchoninic acid assay (Pierce BCA Protein Assay Kit, Thermo Fisher) and sample volumes were adapted to 30 μg of total protein. Samples were loaded onto NuPAGE 12% Bis-Tris gels (Invitrogen). Gels were
- ⁵⁴⁴ loaded in the following repeating pattern: protein ladder, SH-SY5Y wt and SH-SY5Y tau^{P301L/S320F}
- cell lysates. SDS-PAGE gels were run at 180 V in MES buffer for 45 min, transferred to nitrocellulose membranes (Invitrogen) using a dry transfer system (iBlot 2 Gel Transfer Device, Invitro-
- 547 gen, Thermo Fisher), membranes were cut vertically along the protein ladder and blocked with 5%
- 548 SureBlock (Lubio Science) in PBST for 30 min at RT. Membranes were incubated with patient
- 549 purified anti-tau autoantibodies 1:100 diluted in in 1% SureBlock in PBST overnight at 4 °C. Neg-
- 550 ative control membranes were not incubated with primary antibodies. Membranes were washed
- 551 3x for 5 min with PBST and then incubated with the following secondary antibodies for 60 min at
- 552 RT: peroxidase AffiniPure® goat anti-mouse IgG H+L (115-035-003, Jackson ImmunoResearch)
- 553 1:10,000 and peroxidase AffiniPure® goat anti-human IgG (H+L) (109-035-088, Jackson Immu-
- noResearch) 1:10,000 diluted with 1% SureBlock in PBST. The negative control was only incu-
- 555 bated with peroxidase goat anti-human secondary antibody. Monoclonal mouse anti-actin clone

556 C4 (MAB1501R, Chemicon) diluted 1:10,000 in 1% SureBlock in PBST was used as a loading

control. Membranes were washed 4x for 5 min with PBST and developed using the Immobilon

558 Crescendo HRP Substrate (Millipore). Individual membranes were imaged using the Fusion SOLO

559 S imaging system (Vilber).

560 Immunofluorescence studies

SH-SY5Y cells were transiently transfected with EGFP-0N4Rtau, using a Lipofectamine[™] 2000 561 562 (Invitrogen) according to manufacturer's protocol and a pRK5 plasmid encoding EGFP-0N4RTau (Addgene #46904, kind gift from Dr. Karen Ashe (52)), a human four-repeat isoform of tau tagged 563 with enhanced green fluorescent protein (EGFP) at the N-terminus. After 48 h cells were fixed 564 with 4% paraformaldehyde, permeabilized with 0.5% BSA, 0.1% Triton[™] X-100 in PBS for 20 565 min at RT and blocked with 0.5% BSA in PBS for 60 min at RT. Primary antibodies were incu-566 bated for 60 min at RT diluted in 0.5% BSA in PBS as follows: purified anti-tau autoantibodies 567 were diluted 1:25, tau mouse monoclonal antibody HT7 (MN1000, Thermo Fisher) diluted 1:500 568 and used as a positive control. Negative controls were not incubated with primary antibodies. Cells 569 570 were washed 3x with 0.5% BSA in PBS and incubated 30 min at RT as follows: for HT7 stains with goat anti-mouse IgG (H+L) cross-adsorbed Alexa Fluor TM 555 (A-21422, Invitrogen) diluted 571 1:500 and counterstained with 4,6-diamidino-2-phenylindole (DAPI) 1mg/mL (Thermo Fisher) 572 573 diluted 1:10,000 in 0.5% BSA in PBS, and for purified anti-tau autoantibodies and negative con-574 trols with biotin AffiniPure® goat anti-human IgG (H+L) (109-065-003, Jackson Immu-575 noResearch) diluted 1:200 in 0.5% BSA in PBS. For purified anti-tau autoantibodies and negative controls, cells were further incubated for 30 min at RT with streptavidin Alexa Fluor[™] 594 con-576 577 jugate diluted 1:200 and counterstained with DAPI diluted 1:10,000 in 0.5% BSA in PBS. Before mounting on glass sides, cells were washed cells 2x for 3 min in 0.5% BSA in PBS. Cells were 578 579 mounted on glass slides with Fluorescence Mounting Medium (Dako) and imaged with a TCS SP5 confocal laser scanning microscope (Leica). Imaging was performed with equipment from the 580 581 Center for Microscopy and Image Analysis, University of Zurich.

582 Statistical analysis

Negative logarithm half-maximal response, or " $log_{10}(EC_{50})$ " values, were determined by fitting the OD = 450nm of the eight dilution points of each sample tested in the automated microELISA to a logistic regression fitter (*21*). Samples with a mean squared residual error >20% of the $log_{10}(EC_{50})$ were classified as non-fittable and were not included in the analysis, as shown before 587 (22). We used $-\log_{10}(EC_{50})$ as a surrogate of antibody titers and classified as positives/ $\alpha \tau^+$ the 588 samples with a high $-\log_{10}(EC_{50})$, using a cut-off of $-\log_{10}(EC_{50}) \ge 1.8$ for the high-throughput 589 screen. In cases where more than one sample was available for the same individual the most recent 590 $\log_{10}(EC_{50})$ value was used.

591 Demographic features were available for the hospital cohort as well as the blood donors' cohort. Age is presented as median with interquartile range and comparisons were performed using non-592 593 parametric Mann-Whitney U test. Categorized age groups and sex of positive and negative are shown as percentages and compared using two-proportions Z-test or γ^2 test for trend in proportions 594 595 as indicated. We used log-binomial regression models (24, 53) to investigate the association be-596 tween the detection of anti-MTBD-tau IgG autoantibodies and different demographic features. 597 Risk ratios and 95% confidence intervals were calculated using MTBD-tau autoreactivity as a binomial outcome. 598

599 Log-binomial regression models used MTBD-tau-autoreactivity as a binomial outcome and were adjusted for age and sex allowing the estimation of age-and-sex adjusted risk ratios and 95% con-600 601 fidence intervals. For the exploration of the association between MTBD-tau-autoreactivity and 602 neurological disorders, we used multivariate log-binomial regression models to estimate age-and-603 sex adjusted risk ratios and 95% confidence intervals using 23 major groups of ICD-10 codes 604 (Supplementary Table S2) corresponding to the neurological disorders identified at least once in the positive samples. For the AD cohort ELISA screen, $log_{10}(EC_{50})$ values were compared using 605 606 Mann-Whitney U test.

607 For the exploration of the association between MTBD-tau-autoreactivity and systemic disorders, 608 we used multivariate log-binomial regression models to estimate age-and-sex adjusted risk ratios and 95% confidence intervals using 27 major groups of ICD-10 codes (Supplementary Table S3) 609 610 or 276 individual ICD-10 codes corresponding to systemic disorders identified at least once in the positive samples and with at least 200 total counts to avoid overinterpretation of rare cases of 611 612 disease. Individual disease entities with a P value < 0.05 Bonferroni corrected for multiple comparisons were included in a multivariate log-binomial regression analysis. In addition, we con-613 614 ducted a Bayesian logistic regression as described recently (21, 54-56), using -logit₁₀(EC₅₀) values 615 as outcome, i.e. without dichotomising the outcome using the R package rstanarm and the follow-616 ing priors (prior=normal[0, 2.5, autoscale=TRUE], prior_intercept = normal[5000, 2.5, au-617 toscale=TRUE)] prior_aux = exponential [1, autoscale =TRUE]. We thereby aimed to confirm the

- 618 positive association between ICD-10 codes previously identified using a conventional logistic re-
- $figure{1}{1}$ gression model with high $-\log_{10}(EC_{50})$ values. Each ICD-10 code was analyzed in an independent
- 620 logistic regression and adjusted for age and sex.
- 621 For the exploration of the association between MTBD-tau-autoreactivity and clinical laboratory
- 622 parameters, we used laboratory parameters with more than 2,000 total counts and calculated me-
- dian values of the total values available for each patient in case of repetition of the clinical labor-
- atory test. We used multivariate log-binomial regression models to estimate age-and-sex adjusted
- risk ratios and 95% confidence intervals using 106 clinical laboratory tests.
- 626 Throughout the manuscript, statistical significance was defined by 2-tailed P value ≤ 0.05 . P values
- 627 were corrected for multiple comparisons using Bonferroni's method when applicable as described
- 628 in each Figure/Table.
- 629 For IgG subclassing, immunoglobulin light chain typing and epitope mapping experiments, we
- $classified samples to be reactive if the OD_{450} was higher than the average of all negatives OD_{450} +$
- 631 2x the standard deviation of the OD₄₅₀ of the negatives.
- 632 For the MTBD-tau aggregation experiments, the mean baseline fluorescence values were sub-
- tracted from the mean fluorescence values at each time point which were then normalized to max-
- 634 imum baseline-subtracted fluorescence values and multiplied by 100 (57).
- 635 Statistical analyses and data visualization were performed using R version 4.3.2 and RStudio ver-
- 636 sion 1.4.1106 (58).

637 List of Supplementary Materials:

- Table S1, S2 and S3
- 639 Fig. S1, S2 and S3

640

641 **References**

- F. Oyama, Y. Ihara, Tau is widely expressed in rat tissues. *J Neurochem* 67, 1235 1244 (1996).
- M. Uhlen, L. Fagerberg, B. M. Hallstrom, C. Lindskog, P. Oksvold, A. Mardinoglu, A.
 Sivertsson, C. Kampf, E. Sjostedt, A. Asplund, I. Olsson, K. Edlund, E. Lundberg, S. Navani,
 C. A. Szigyarto, J. Odeberg, D. Djureinovic, J. O. Takanen, S. Hober, T. Alm, P. H. Edqvist,
 H. Berling, H. Tegel, J. Mulder, J. Rockberg, P. Nilsson, J. M. Schwenk, M. Hamsten, K. von
 Feilitzen, M. Forsberg, L. Persson, F. Johansson, M. Zwahlen, G. von Heijne, J. Nielsen, F.
 Ponten, Proteomics. Tissue-based map of the human proteome. *Science* 347, 1260419
 (2015).
- K. S. Kosik, C. L. Joachim, D. J. Selkoe, Microtubule-associated protein tau (tau) is a major
 antigenic component of paired helical filaments in Alzheimer disease. *Proc Natl Acad Sci U S A* 83, 4044-4048 (1986).
- 6544.C. L. Joachim, J. H. Morris, K. S. Kosik, D. J. Selkoe, Tau antisera recognize neurofibrillary655tangles in a range of neurodegenerative disorders. Ann Neurol 22, 514-520 (1987).
- B. J. Hanseeuw, R. A. Betensky, H. I. L. Jacobs, A. P. Schultz, J. Sepulcre, J. A. Becker, D. M.
 O. Cosio, M. Farrell, Y. T. Quiroz, E. C. Mormino, R. F. Buckley, K. V. Papp, R. A. Amariglio,
 I. Dewachter, A. Ivanoiu, W. Huijbers, T. Hedden, G. A. Marshall, J. P. Chhatwal, D. M.
 Rentz, R. A. Sperling, K. Johnson, Association of Amyloid and Tau With Cognition in
 Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurol 76, 915-924 (2019).
- 6. N. Mattsson, H. Zetterberg, S. Janelidze, P. S. Insel, U. Andreasson, E. Stomrud, S.
 Palmqvist, D. Baker, C. A. Tan Hehir, A. Jeromin, D. Hanlon, L. Song, L. M. Shaw, J. Q.
 Trojanowski, M. W. Weiner, O. Hansson, K. Blennow, A. Investigators, Plasma tau in
 Alzheimer disease. *Neurology* 87, 1827-1835 (2016).
- S. Janelidze, N. Mattsson, S. Palmqvist, R. Smith, T. G. Beach, G. E. Serrano, X. Chai, N. K.
 Proctor, U. Eichenlaub, H. Zetterberg, K. Blennow, E. M. Reiman, E. Stomrud, J. L. Dage,
 O. Hansson, Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers,
 differential diagnosis, neuropathology and longitudinal progression to Alzheimer's
 dementia. *Nat Med* 26, 379-386 (2020).
- M. M. Mielke, C. E. Hagen, A. M. V. Wennberg, D. C. Airey, R. Savica, D. S. Knopman, M.
 M. Machulda, R. O. Roberts, C. R. Jack, R. C. Petersen, J. L. Dage, Association of Plasma
 Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia
 in the Mayo Clinic Study on Aging. JAMA Neurol 74, 1073-1080 (2017).
- S. Palmqvist, P. Tideman, N. Mattsson-Carlgren, S. E. Schindler, R. Smith, R. Ossenkoppele,
 S. Calling, T. West, M. Monane, P. B. Verghese, J. B. Braunstein, K. Blennow, S. Janelidze,
 E. Stomrud, G. Salvado, O. Hansson, Blood Biomarkers to Detect Alzheimer Disease in
 Primary Care and Secondary Care. JAMA, (2024).
- 67810.A. A. Asuni, A. Boutajangout, D. Quartermain, E. M. Sigurdsson, Immunotherapy targeting679pathological tau conformers in a tangle mouse model reduces brain pathology with680associated functional improvements. J Neurosci 27, 9115-9129 (2007).
- A. Boutajangout, J. Ingadottir, P. Davies, E. M. Sigurdsson, Passive immunization targeting
 pathological phospho-tau protein in a mouse model reduces functional decline and clears
 tau aggregates from the brain. *J Neurochem* **118**, 658-667 (2011).

- E. E. Congdon, E. M. Sigurdsson, Tau-targeting therapies for Alzheimer disease. *Nat Rev Neurol* 14, 399-415 (2018).
- 68613.T. L. Rothstein, Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in687the Aged. Front Immunol 7, 127 (2016).
- H. U. Lutz, C. J. Binder, S. Kaveri, Naturally occurring auto-antibodies in homeostasis and
 disease. *Trends Immunol* **30**, 43-51 (2009).
- I. R. Jaycox, Y. Dai, A. M. Ring, Decoding the autoantibody reactome. *Science* 383, 705 707 (2024).
- N. R. Florance, R. L. Davis, C. Lam, C. Szperka, L. Zhou, S. Ahmad, C. J. Campen, H. Moss,
 N. Peter, A. J. Gleichman, C. A. Glaser, D. R. Lynch, M. R. Rosenfeld, J. Dalmau, Anti-Nmethyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. *Ann Neurol* 66, 11-18 (2009).
- V. A. Lennon, D. M. Wingerchuk, T. J. Kryzer, S. J. Pittock, C. F. Lucchinetti, K. Fujihara, I.
 Nakashima, B. G. Weinshenker, A serum autoantibody marker of neuromyelitis optica:
 distinction from multiple sclerosis. *Lancet* 364, 2106-2112 (2004).
- I. Ferrero, L. Williams, H. Stella, K. Leitermann, A. Mikulskis, J. O'Gorman, J. Sevigny, Firstin-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab
 (BIIB037) in mild-to-moderate Alzheimer's disease. *Alzheimers Dement (N Y)* 2, 169-176
 (2016).
- 70319.A. Bartos, L. Fialová, J. Švarcová, Lower Serum Antibodies Against Tau Protein and Heavy704Neurofilament in Alzheimer's Disease. J Alzheimers Dis 64, 751-760 (2018).
- Y. Kronimus, A. Albus, M. Balzer-Geldsetzer, S. Straub, E. Semler, M. Otto, J. Klotsche, R.
 Dodel, L. Consortium, D. Mengel, Naturally Occurring Autoantibodies against Tau Protein
 Are Reduced in Parkinson's Disease Dementia. *PLoS One* **11**, e0164953 (2016).
- 708 21. M. Emmenegger, E. De Cecco, D. Lamparter, R. P. B. Jacquat, J. Riou, D. Menges, T. Ballouz, 709 D. Ebner, M. M. Schneider, I. C. Morales, B. Dogancay, J. Guo, A. Wiedmer, J. Domange, 710 M. Imeri, R. Moos, C. Zografou, L. Batkitar, L. Madrigal, D. Schneider, C. Trevisan, A. 711 Gonzalez-Guerra, A. Carrella, I. L. Dubach, C. K. Xu, G. Meisl, V. Kosmoliaptsis, T. 712 Malinauskas, N. Burgess-Brown, R. Owens, S. Hatch, J. Mongkolsapaya, G. R. Screaton, K. 713 Schubert, J. D. Huck, F. Liu, F. Pojer, K. Lau, D. Hacker, E. Probst-Muller, C. Cervia, J. 714 Nilsson, O. Boyman, L. Saleh, K. Spanaus, A. von Eckardstein, D. J. Schaer, N. Ban, C. J. Tsai, 715 J. Marino, G. F. X. Schertler, N. Ebert, V. Thiel, J. Gottschalk, B. M. Frey, R. R. Reimann, S. 716 Hornemann, A. M. Ring, T. P. J. Knowles, M. A. Puhan, C. L. Althaus, I. Xenarios, D. I. Stuart, 717 A. Aguzzi, Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a 718 large European metropolitan region. iScience 26, 105928 (2023).
- A. Senatore, K. Frontzek, M. Emmenegger, A. Chincisan, M. Losa, R. Reimann, G. Horny, J.
 Guo, S. Fels, S. Sorce, C. Zhu, N. George, S. Ewert, T. Pietzonka, S. Hornemann, A. Aguzzi,
 Protective anti-prion antibodies in human immunoglobulin repertoires. *EMBO Mol Med* e12739 (2020).
- M. Emmenegger, C. Zografou, D. Yile, L. R. Hoyt, R. Gudneppanavar, A. Chincisan, H.
 Rehrauer, F. J. Noé, N. Zajac, G. Meisl, M. M. Schneider, H. Nguyen, K. Höpker, T. P. J.
 Knowles, M. Sospedra, R. Martin, A. M. Ring, S. Leeds, S. C. Eisenbarth, M. E. Egan, E. M.
 Bruscia, A. Aguzzi, The Cystic Fibrosis Transmembrane Regulator Controls Tolerogenic
 Responses to Food Allergens in Mice and Humans. *medRxiv*, (2024).

- F. A. Diaz-Quijano, A simple method for estimating relative risk using logistic regression.
 BMC Med Res Methodol 12, 14 (2012).
- M. W. Donoghoe, I. C. Marschner, Logbin: An R Package for Relative Risk Regression Using
 the Log-Binomial Model. *Journal of Statistical Software* 86, (2018).
- R. de Silva, T. Lashley, G. Gibb, D. Hanger, A. Hope, A. Reid, R. Bandopadhyay, M. Utton,
 C. Strand, T. Jowett, N. Khan, B. Anderton, N. Wood, J. Holton, T. Revesz, A. Lees,
 Pathological inclusion bodies in tauopathies contain distinct complements of tau with
 three or four microtubule-binding repeat domains as demonstrated by new specific
 monoclonal antibodies. *Neuropathol Appl Neurobiol* 29, 288-302 (2003).
- M. Emmenegger, E. De Cecco, M. Hruska-Plochan, T. Eninger, M. M. Schneider, M. Barth,
 E. Tantardini, P. de Rossi, M. Bacioglu, R. G. Langston, A. Kaganovich, N. BengoaVergniory, A. Gonzalez-Guerra, M. Avar, D. Heinzer, R. Reimann, L. M. Hasler, T. W.
 Herling, N. S. Matharu, N. Landeck, K. Luk, R. Melki, P. J. Kahle, S. Hornemann, T. P. J.
 Knowles, M. R. Cookson, M. Polymenidou, M. Jucker, A. Aguzzi, LAG3 is not expressed in
 human and murine neurons and does not modulate alpha-synucleinopathies. *EMBO Mol Med* 13, e14745 (2021).
- A. Apetri, R. Crespo, J. Juraszek, G. Pascual, R. Janson, X. Zhu, H. Zhang, E. Keogh, T. Holland, J. Wadia, H. Verveen, B. Siregar, M. Mrosek, R. Taggenbrock, J. Ameijde, H. Inganäs, M. van Winsen, M. H. Koldijk, D. Zuijdgeest, M. Borgers, K. Dockx, E. J. M. Stoop, W. Yu, E. C. Brinkman-van der Linden, K. Ummenthum, K. van Kolen, M. Mercken, S. Steinbacher, D. de Marco, J. J. Hoozemans, I. A. Wilson, W. Koudstaal, J. Goudsmit, A common antigenic motif recognized by naturally occurring human V. Acta Neuropathol Commun 6, 43 (2018).
- M. P. Pase, A. S. Beiser, J. J. Himali, C. L. Satizabal, H. J. Aparicio, C. DeCarli, G. Chêne, C.
 Dufouil, S. Seshadri, Assessment of Plasma Total Tau Level as a Predictive Biomarker for
 Dementia and Related Endophenotypes. *JAMA Neurol* **76**, 598-606 (2019).
- 30. E. Barini, G. Plotzky, Y. Mordashova, J. Hoppe, E. Rodriguez-Correa, S. Julier, F. LePrieult,
 I. Mairhofer, M. Mezler, S. Biesinger, M. Cik, M. W. Meinhardt, E. Ercan-Herbst, D. E.
 Ehrnhoefer, A. Striebinger, K. Bodie, C. Klein, L. Gasparini, K. Schlegel, Tau in the brain
 interstitial fluid is fragmented and seeding-competent. *Neurobiol Aging* 109, 64-77
 (2022).
- M. W. Donoghoe, I. C. Marschner, logbin: An R Package for Relative Risk Regression Using
 the Log-Binomial Model. *Journal of Statistical Software* 86, 21 (2018).
- 32. L. Dahm, C. Ott, J. Steiner, B. Stepniak, B. Teegen, S. Saschenbrecker, C. Hammer, K.
 Borowski, M. Begemann, S. Lemke, K. Rentzsch, C. Probst, H. Martens, J. Wienands, G.
 Spalletta, K. Weissenborn, W. Stöcker, H. Ehrenreich, Seroprevalence of autoantibodies
 against brain antigens in health and disease. *Ann Neurol* **76**, 82-94 (2014).
- Z. Y. Yu, W. W. Li, H. M. Yang, N. B. Manucat-Tan, J. Wang, Y. R. Wang, B. L. Sun, Z. C. Hu,
 L. L. Zhang, L. Tan, J. Deng, Y. H. Liu, Naturally Occurring Antibodies to Tau Exists in Human
 Blood and Are Not Changed in Alzheimer's Disease. *Neurotox Res* 37, 1029-1035 (2020).
- Y. Tsuboi, R. J. Uitti, M. B. Delisle, J. J. Ferreira, C. Brefel-Courbon, O. Rascol, B. Ghetti, J.
 R. Murrell, M. Hutton, M. Baker, Z. K. Wszolek, Clinical features and disease haplotypes of individuals with the N279K tau gene mutation: a comparison of the pallidopontonigral degeneration kindred and a French family. *Arch Neurol* 59, 943-950 (2002).

- 35. I. Sotiropoulos, M. C. Galas, J. M. Silva, E. Skoulakis, S. Wegmann, M. B. Maina, D. Blum,
 C. L. Sayas, E. M. Mandelkow, E. Mandelkow, M. G. Spillantini, N. Sousa, J. Avila, M.
 Medina, A. Mudher, L. Buee, Atypical, non-standard functions of the microtubule
 associated Tau protein. *Acta Neuropathol Commun* 5, 91 (2017).
- M. M. Rinschen, M. Gödel, F. Grahammer, S. Zschiedrich, M. Helmstädter, O. Kretz, M.
 Zarei, D. A. Braun, S. Dittrich, C. Pahmeyer, P. Schroder, C. Teetzen, H. Gee, G. Daouk, M.
 Pohl, E. Kuhn, B. Schermer, V. Küttner, M. Boerries, H. Busch, M. Schiffer, C. Bergmann,
 M. Krüger, F. Hildebrandt, J. Dengjel, T. Benzing, T. B. Huber, A Multi-layered Quantitative
 In Vivo Expression Atlas of the Podocyte Unravels Kidney Disease Candidate Genes. *Cell Rep* 23, 2495-2508 (2018).
- K. H. Ho, X. Yang, A. B. Osipovich, O. Cabrera, M. L. Hayashi, M. A. Magnuson, G. Gu, I.
 Kaverina, Glucose Regulates Microtubule Disassembly and the Dose of Insulin Secretion
 via Tau Phosphorylation. *Diabetes* 69, 1936-1947 (2020).
- 78538.L. Vallés-Saiz, R. Peinado-Cahuchola, J. Ávila, F. Hernández, Microtubule-associated786protein tau in murine kidney: role in podocyte architecture. *Cell Mol Life Sci* **79**, 97 (2022).
- 39. E. E. Congdon, C. Ji, A. M. Tetlow, Y. Jiang, E. M. Sigurdsson, Tau-targeting therapies for
 Alzheimer disease: current status and future directions. *Nat Rev Neurol* 19, 715-736
 (2023).
- ClinicalTrial.gov, NCT05269394, Dominantly Inherited Alzheimer Network Trial: An
 Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in
 Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation
 (DIAN-TU),
- 794
 (https://clinicaltrials.gov/study/NCT05269394?cond=Alzheimer%20Disease&term=E281

 795
 <u>4&rank=1</u>) (2023).
- M. E. Barton, B. Van Den Steen, H. L. G. Van Tricht, W. Byrnes, F. E. Purcell, S. A. Southcott,
 D. Raby, Y. I. Starshinov, C. Ewen, Update on the TOGETHER study: a patient- and
 investigator-blind, randomized, placebo-controlled study evaluating the efficacy, safety
 and tolerability of bepranemab, UCB0107, in prodromal-to-mild Alzheimer's disease. *Alzheimer's & Dementia* 18, e068973 (2022).
- 42. A. Moscoso, M. J. Grothe, N. J. Ashton, T. K. Karikari, J. Lantero Rodríguez, A. Snellman,
 M. Suárez-Calvet, K. Blennow, H. Zetterberg, M. Schöll, A. s. D. N. Initiative, Longitudinal
 Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With
 Neurodegeneration in Alzheimer Disease. JAMA Neurol 78, 396-406 (2021).
- 805 N. R. Barthélemy, Y. Li, N. Joseph-Mathurin, B. A. Gordon, J. Hassenstab, T. L. S. Benzinger, 43. 806 V. Buckles, A. M. Fagan, R. J. Perrin, A. M. Goate, J. C. Morris, C. M. Karch, C. Xiong, R. 807 Allegri, P. C. Mendez, S. B. Berman, T. Ikeuchi, H. Mori, H. Shimada, M. Shoji, K. Suzuki, J. Noble, M. Farlow, J. Chhatwal, N. R. Graff-Radford, S. Salloway, P. R. Schofield, C. L. 808 809 Masters, R. N. Martins, A. O'Connor, N. C. Fox, J. Levin, M. Jucker, A. Gabelle, S. Lehmann, C. Sato, R. J. Bateman, E. McDade, D. I. A. Network, A soluble phosphorylated tau 810 signature links tau, amyloid and the evolution of stages of dominantly inherited 811 Alzheimer's disease. Nat Med 26, 398-407 (2020). 812
- 44. T. K. Karikari, T. A. Pascoal, N. J. Ashton, S. Janelidze, A. L. Benedet, J. L. Rodriguez, M.
 Chamoun, M. Savard, M. S. Kang, J. Therriault, M. Schöll, G. Massarweh, J. P. Soucy, K.
 Höglund, G. Brinkmalm, N. Mattsson, S. Palmqvist, S. Gauthier, E. Stomrud, H. Zetterberg,

O. Hansson, P. Rosa-Neto, K. Blennow, Blood phosphorylated tau 181 as a biomarker for
 Alzheimer's disease: a diagnostic performance and prediction modelling study using data
 from four prospective cohorts. *Lancet Neurol* 19, 422-433 (2020).

- 45. J. C. Park, S. H. Han, D. Yi, M. S. Byun, J. H. Lee, S. Jang, K. Ko, S. Y. Jeon, Y. S. Lee, Y. K. Kim,
 B. Y. Lee, I. Mook-Jung, Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and
 neurodegeneration in Alzheimer's disease. *Brain* 142, 771-786 (2019).
- S. Palmqvist, S. Janelidze, Y. T. Quiroz, H. Zetterberg, F. Lopera, E. Stomrud, Y. Su, Y. Chen,
 G. E. Serrano, A. Leuzy, N. Mattsson-Carlgren, O. Strandberg, R. Smith, A. Villegas, D.
 Sepulveda-Falla, X. Chai, N. K. Proctor, T. G. Beach, K. Blennow, J. L. Dage, E. M. Reiman,
 O. Hansson, Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs
 Other Neurodegenerative Disorders. JAMA 324, 772-781 (2020).
- K. Yanamandra, T. K. Patel, H. Jiang, S. Schindler, J. D. Ulrich, A. L. Boxer, B. L. Miller, D. R.
 Kerwin, G. Gallardo, F. Stewart, M. B. Finn, N. J. Cairns, P. B. Verghese, I. Fogelman, T.
 West, J. Braunstein, G. Robinson, J. Keyser, J. Roh, S. S. Knapik, Y. Hu, D. M. Holtzman,
 Anti-tau antibody administration increases plasma tau in transgenic mice and patients
 with tauopathy. *Sci Transl Med* 9, (2017).
- 48. M. M. Mielke, J. L. Dage, R. D. Frank, A. Algeciras-Schimnich, D. S. Knopman, V. J. Lowe,
 6. Bu, P. Vemuri, J. Graff-Radford, C. R. Jack, Jr., R. C. Petersen, Performance of plasma
 phosphorylated tau 181 and 217 in the community. *Nat Med* 28, 1398-1405 (2022).
- Klein, Activation of
 C. M. Hedgepeth, L. J. Conrad, J. Zhang, H. C. Huang, V. M. Lee, P. S. Klein, Activation of
 the Wnt signaling pathway: a molecular mechanism for lithium action. *Dev Biol* 185, 8291 (1997).
- 83850.J. J. Bunker, S. A. Erickson, T. M. Flynn, C. Henry, J. C. Koval, M. Meisel, B. Jabri, D. A.839Antonopoulos, P. C. Wilson, A. Bendelac, Natural polyreactive IgA antibodies coat the840intestinal microbiota. *Science* **358**, (2017).
- H. Mouquet, J. F. Scheid, M. J. Zoller, M. Krogsgaard, R. G. Ott, S. Shukair, M. N. Artyomov,
 J. Pietzsch, M. Connors, F. Pereyra, B. D. Walker, D. D. Ho, P. C. Wilson, M. S. Seaman, H.
 N. Eisen, A. K. Chakraborty, T. J. Hope, J. V. Ravetch, H. Wardemann, M. C. Nussenzweig,
 Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. *Nature* 467, 591-595 (2010).
- B. R. Hoover, M. N. Reed, J. Su, R. D. Penrod, L. A. Kotilinek, M. K. Grant, R. Pitstick, G. A.
 Carlson, L. M. Lanier, L. L. Yuan, K. H. Ashe, D. Liao, Tau mislocalization to dendritic spines
 mediates synaptic dysfunction independently of neurodegeneration. *Neuron* 68, 10671081 (2010).
- 85053.L. A. McNutt, C. Wu, X. Xue, J. P. Hafner, Estimating the relative risk in cohort studies and851clinical trials of common outcomes. Am J Epidemiol 157, 940-943 (2003).
- M. Emmenegger, V. Emmenegger, S. M. Shambat, T. C. Scheier, A. Gomez-Mejia, C. C.
 Chang, P. D. Wendel-Garcia, P. K. Buehler, T. Buettner, D. Roggenbuck, S. D. Brugger, K.
 B. M. Frauenknecht, Antiphospholipid antibodies are enriched post-acute COVID-19 but
 do not modulate the thrombotic risk. *Clin Immunol* 257, 109845 (2023).
- 856 55. M. Emmenegger, V. Emmenegger, in *Zenodo, h<u>ttps://doi.org/10.5281/zenodo.10051979.</u>
 857 (2023).*
- 85856.M. Losa, M. Emmenegger, P. De Rossi, P. M. Schürch, T. Serdiuk, N. Pengo, D. Capron, D.859Bieli, N. J. Rupp, M. C. Carta, K. J. Karl J Frontzek, V. Lysenko, R. R. Reimann, A. K. K.

Lakkaraju, M. Nuvolone, G. T. Westermark, K. P. R. Nilsson, M. Polymenidou, A. P. A. 860 861 Theocharides, Simone Hornemann, P. Picotti, A. Aguzzi, The ASC inflammasome adapter 862 controls the extent of peripheral protein aggregate deposition in inflammation-863 associated amyloidosis. BioXriv, doi: https://doi.org/10.1101/2021.05.01.442282, (2023). C. D. Orrú, J. Yuan, B. S. Appleby, B. Li, Y. Li, D. Winner, Z. Wang, Y. A. Zhan, M. Rodgers, 864 57. J. Rarick, R. E. Wyza, T. Joshi, G. X. Wang, M. L. Cohen, S. Zhang, B. R. Groveman, R. B. 865 Petersen, J. W. Ironside, M. E. Quiñones-Mateu, J. G. Safar, Q. Kong, B. Caughey, W. Q. 866 Zou, Prion seeding activity and infectivity in skin samples from patients with sporadic 867 868 Creutzfeldt-Jakob disease. Sci Transl Med 9, (2017). 869 58. RStudioTeam. (RStudio, PBC, Boston, MA, 2021).

870

871 Acknowledgments:

The authors wish to thank the hospital patients and blood donors for their generous altruistic con-872 873 tributions to this study. Imaging was performed with equipment maintained by the Center for Microscopy and Image Analysis, University of Zurich. We thank Prof. Rohan de Silva (UCL Queen 874 875 Square Institute of Neurology, London, UK) for providing the purified anti-MTBD-tau antibody 876 RD4. We thank Dr. Marco Losa for the generous provision of secondary antibodies for light chain 877 typing and Magdalena Bialkowska, Lisa Caflisch, Berre Doğançay, Julie Domange, Marigona Imeri, Lorène Mottier, Rea Müller, Antonella Rosati, Dezirae Schneider, and Anne Wiedmer for 878 879 help with the high-throughput assays. Insightful advice about programming in R software was 880 provided by Reto Guadagnini.

881

882 Funding:

- 883 University of Zürich, Candoc grant FK-19-025 (ADM)
- 884 Swiss Personalised Health Network, SPHN, driver project grant 2017DRI17 (AA)
- 885 Swiss National Foundation SNF (SNSF grant ID 179040 and grant ID 207872, Sinergia grant ID
- 886 183563) (AA)
- 887 European Research Council ERC Prion2020, 670958 (AA)
- 888 Nomis Foundation (AA)
- 889 Innovation Fund of the University Hospital Zurich (INOV00096) (AA)
- 890 University Hospital Zurich Foundation grant USZF27101 (with contributions of the NOMIS Foun-
- dation, the Schwyzer Winiker Stiftung, and the Baugarten Stiftung, AA, ME)
- HMZ ImmunoTarget grant, Stiftung Neuropath and GELU Foundation (AA)

Michael J. Fox Foundation (grant ID MJFF-020710 and MJFF-021073) (SH).

894

895 Author contributions:

Conceived and designed the experiments: ADM, SH, AA. Supervised the study: SH, AA. Per-896 897 formed tau protein purification: ADM, EDC, JG. Performed tau microELISA automated screen: ADM, ME. Performed amyloid-ß pyroglutamate and cellular prion protein microELISA auto-898 899 mated screen: MC, KF, ME. Maintained microELISA automated platform: ME. Performed puri-900 fication, validation and characterization of anti-tau autoantibodies: ADM, JG. Maintained the clinical database: ME, AC. Performed data analysis and visualization: ADM. Wrote the first draft of 901 manuscript: ADM. Corrected and advised on subsequent versions of the manuscript: ADM, ME, 902 903 SH, AA. All authors reviewed and approved the final version of the manuscript and consented to be accountable for the work. 904

905

906 **Competing interests:**

ADM has received a research grant from University of Zurich; KF has received research grants 907 from Ono Pharmaceuticals and Theodor Ida Herzog Egli Stiftung, consulting fees from Acumen 908 909 Collective and Ionis Pharmaceuticals, support for attending meetings/travel from Euro-CNS and 910 has participated on the Advisory Board of Mabylon AG; AA has received research grants from the 911 Swiss Personalized Health Network, Swiss National Foundation, European Research Council and 912 Nomis Foundation and is a member of the Board of Directors of Mabylon AG. Mabylon AG pro-913 duces therapeutic human antibodies. Mabylon AG had no insight and no influence on the current study. All authors report no other relationships or activities that could appear to have influenced 914 915 the submitted work.

916

917 Data and materials availability:

Data and material requests should be addressed to the corresponding authors. Materials will be shared upon reasonable request, given the approval by an ethics committee or review board and a material transfer agreement.





922 923

Fig. 1. Study overview and seroprevalence of anti-MTBD-tau IgG autoantibodies. A. 924 925 Flowchart of the study design. **B.-C.** Distribution of $-\log_{10}(EC_{50})$ values obtained from the micro-926 ELISA screen of hospital (B) and blood donor (C) plasma samples. D. Age- and sex-adjusted risk 927 ratio ratios and 95% confidence intervals (CI; I bars) for the detection of anti-tau autoantibodies 928 in hospital and blood-bank plasma samples. E. Replicability of microELISA duplicates with inde-929 pendent estimation of the $-\log_{10}(EC_{50})$ values. Dashed lines: cut-off value of $-\log_{10}(EC_{50}) = 1.8$. F. 930 -log₁₀(EC₅₀) values of samples tested by microELISA against MTBD-tau and amyloid-ß pyroglutamate. G. Same as shown in (F), but for samples tested against MTBD-tau and the cellular prion 931 932 protein (PrP^C).

933





Magalhães et al, Figure 2

Fig. 2. Biophysical characterization of samples from $\alpha \tau^+$ **patients. A**. Indirect ELISA of purified anti-MTBD-tau autoantibodies from four $\alpha \tau^+$ samples and from 6 pooled $\alpha \tau^+$ samples. All antibodies were assayed at the same concentration to compare their EC₅₀ to that of RD4. EC₅₀ values are indicated in the Figure. n.d.: not determined. **B.** Principle of competition ELISA. **C.** Competition ELISA of purified anti-tau autoantibodies from four $\alpha \tau^+$ patients against albumin, recombinant MTBD-tau, synthetic peptides spanning the sequence of MTBD-tau and synthetic TREM2 RD4 (anti-4-repeat-isoform) antibody: positive control. Mean values ± SD of two repli-

942 cates. **D.** Indirect ELISA to assess the reactivity of purified anti-tau autoantibodies against albumin, cardiolipin, double-stranded DNA, insulin, lipopolysaccharides (LPS), MTBD-tau and un-943 944 coated plates. Positive controls were as follows: RD4 antibody for MTBD-tau, anti-DNP antibody for cardiolipin, albumin and DNA and the IKC pool of 20 heparin plasma samples for insulin, LPS 945 and uncoated plates. Mean values \pm SD of two replicates are shown. E. Representative immuno-946 fluorescence images of SH-SY5Y cells expressing EGFP-0N4R-tau using affinity-purified anti-947 tau autoantibodies. HT7 pan-tau antibody: positive control. No primary antibody: negative control. 948 Scale bar: 60 µm. F. Western blot of cell lysates from wild-type (SH-SY5Y WT) or tau^{P301L/S320F}-949 950 overexpressing cells (SH-SY5Y tau) using purified anti-tau autoantibodies from four $\alpha \tau^+$ patients. Positive control: RD4. Negative control: omission of primary antibody. G. IgG subclass typing of 951 13 $\alpha \tau^+$ plasma samples. Gray and white boxes: reactive and non-reactive samples, respectively. **H.** 952 κ/λ light chain typing of the samples in F. I. Epitope mapping of the samples in Fig. 2F against 953 954 25mer MTBD-tau peptides with 10 residues overlap. Vertical axis: sequences of the MTBD-tau 955 peptides covering the sequence of MTBD-tau.





Fig. 3. Natural *α***τ autoantibodies inhibit tau aggregation and impair tau detection. A.** Kinetic aggregation curves of MTBD-tau followed by ThT fluorescence in the absence (n=12) or presence of purified *α***τ** autoantibodies (patient P7 (n=4) and P8 (n=2)) or antibodies from an *α***τ**⁻ sample (n=6). Stoichiometric ratios as indicated. Gray lines indicate individual replicates and black lines the average of the replicates. **B.** Principle of the competition sandwich ELISA. **C.** Competitive

- sandwich ELISA to assess the ability of purified anti-tau autoantibodies with matching (P4-P6)
- and non-matching (P2 and P3) epitopes to the commercial detection antibody, ab64193, to impair
- 964 the detection of free tau⁴⁴¹ spiked in plasma (dark blue). Serial dilutions of purified anti-tau anti-
- 965 bodies are shown in (C) and binding at highest anti-tau antibody concentrations in (D).

966



968

Magalhães et al, Figure 4

969 Fig. 4. Demographic characteristics of hospital patients' cohort. A. Age and sex pyramid of 970 positive and negative individuals. B. Percentage of positives across decadic age groups. The num-971 bers on top of each bar correspond to the positivity rates. Numbers inside bars: $\alpha \tau^+$ vs tested samples in each age group. χ^2 test for trend in proportions. C. Risk ratios $\pm 95\%$ confidence intervals 972 (CI) for $\alpha \tau^+$ autoantibodies according to sex and age groups. Asterisks: P < 0.05 after Bonferroni 973 correction. **D.** Break-down of samples by clinical department. Asterisks: P < 0.05 (two-proportions 974 975 z-test with Bonferroni correction). **E.** Age- and sex-adjusted risk ratios \pm 95% CI for $\alpha \tau^+$ samples by clinical department. Asterisks: P < 0.05 after Bonferroni correction. 976

Α										
Neurologic disease			Prevalence					Adjusted		P value
			os. r	n°/total n° (%	5)			Risk Ratio (95% CI)		
Dementia										
Alzheimer's	disease		2/	31 (6.45)	←	+	>	1.02 (0.1	7-2.96)	0.975
Non-Alzheim	ner's dementia		11/	211 (5.21)	←			0.88 (0.4	6-1.48)	0.653
Epilepsy			39/	905 (4.31)	-	-		0.87 (0.6	62-1.17)	0.378
Headache dis	leadache disorders									
Migraine			26/	440 (5.91)				1.23 (0.8	32-1.76)	0.283
Other heada	che disorders		21/	391 (5.37)	-	-		1.09 (0.6	69-1.61)	0.692
Meningitis, En	cephalitis or N	lyelitis	4/	133 (3.01)	-			0.64 (0.2	20-1.45)	0.362
Movement disorders										
Parkinson's	disease		12/	166 (7.23)		-		1.35 (0.7	3-2.21)	0.288
Secondary p	arkinsonism		3/	15 (20.00)			>	3.92 (1.0	6-8.56)	0.007
Atypical park	kinsonism			0/9 (0)						
Essential tre	mor		3/	57 (5.26)	←	•		0.97 (0.2	25-2.41)	0.955
Dystonia			2/	42 (4.76)	•	•	>	0.91 (0.1	5-2.66)	0.886
Myoclonus	Myoclonus			29 (13.79)			>	2.81 (0.9	91-5.94)	0.021
Multiple Sclerosis			11/	290 (3.79)	←			0.83 (0.4	3-1.40)	0.521
Neuromuscular disorders										
Neuropathies	s		78/	1445 (5.40)		-		1.06 (0.8	84-1.31)	0.626
Myoneural ju	Myoneural junction disorders			45 (4.44)	←	•		0.87 (0.1	5-2.56)	0.840
Myopathies			6/3	204 (2.94)	-			0.60 (0.2	24-1.20)	0.202
Other neurodegenerative disorders										
Hereditary ataxia/spastic paraplegia			1/	(12 (8.33)	←	-	\longrightarrow	1.59 (0.0	9-1.08)	0.621
Motor neuron disease				0/26 (0)						
Huntington's	Huntington's disease			0/1 (0)						
Sleep disorders			53/	883 (6.00)				1.23 (0.9	93-1.59)	0.131
Stroke										
Transient ischemic attack			10/	239 (4.18)	←			0.78 (0.4	0-1.36)	0.433
Infarction			42/	776 (5.41)		•		1.02 (0.7	(4-1.36)	0.881
Hemorrhage			11/	295 (3.73)	←■			0.71 (0.37-1.21)		0.259
						1 1				
					0.5	1 1.5 Risk Ratio	2			
D						TASK TABLE				
В	MTBD-tau IgG					tau441 lg	IG			
										7
	•	P = 0.124	Ļ				P	= 0.231		



977

Fig. 5. Age- and sex-adjusted risk ratios of MTBD-tau-autoreactivity for major groups of neurological disorders and reactivity profiles for AD screen. A. Age- and sex-adjusted risk ratios and 95% confidence intervals (CI; I bars) for $\alpha \tau^+$ autoantibodies according to different

Magalhães et al, Figure 5

- 981 groups of neurological disorders. No P values remained significant after Bonferroni correction. **B.**
- 982 Boxplots showing the 25th, 50th (median) and 75th percentiles of the reactivity profiles for AD and
- 983 control patients (Mann-Whitney U test).

984



985

986Fig. 6. Association of MTBD-tau IgG autoantibodies and systemic disorders and clinical la-987boratory data. A. Age- and sex-adjusted risk ratios $\pm 95\%$ CI (bars) for ατ⁺ autoantibodies988grouped 27 different main systemic clinical conditions. Asterisks: P < 0.05 after Bonferroni cor-</td>989rection. B. -log₁₀(P value) of the log-binomial regression for the presence of plasma MTBD-tau990IgG autoantibodies for 276 disorders according to ICD-10 codes and adjusted for age and sex.991Triangles pointing upwards and downwards: positive and coefficients, respectively; gray dashed992line: P < 0.05 after Bonferroni correction (here and henceforth). P values significant after Bonfer-</td>

993 roni adjustment are labelled with the ICD codes. C. Same as (A), but according to individual dis-994 ease entities from (B). D. Bayesian logistic regression adjusted for age and sex on ICD-10 codes 995 significantly associated in B. and using $-\log_{10}(EC_{50})$ as continuous outcome (odds ratio $\pm 95\%$ credible intervals). This analysis confirms the positive association of these ICD-10 codes with $\alpha \tau$ 996 997 reactivity (from B). E. -log₁₀(P value) of the log-binomial regression for the presence of plasma MTBD-tau IgG autoantibodies and clinical laboratory parameters. P values significant after Bon-998 999 ferroni adjustment are labelled with the ICD codes. The gray dashed line indicates the significance 1000 level after Bonferroni correction (<0.05/106=0.00047). eGFR CKD-EPI 2009: estimated glomer-1001 ular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration 2009 equation; 1002 eGFR BIS1: estimated glomerular filtration rate using the older adults Berlin Initiative Study 1 equation. INR: international normalized ratio. LDL: low-density lipoprotein. HDL: high-density 1003 1004 lipoprotein. **F.** Calculated prevalence of different ICD-10 codes in the total cohort (dark blue), ατ⁻ 1005 (intermediate blue) and $\alpha \tau^+$ samples (light blue).